Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals to $384 from $342 and keeps an Overweight rating on the shares post the Q1 results. The analyst continues to see the company’s cystic fibrosis franchise supporting a "floor value" with its pipeline assets providing additional upside. The firm notes that Vertex has multiple pipeline updates in 2023.